JSSH
VRDN icon

J. Safra Sarasin Holding’s Viridian Therapeutics VRDN Stock Holding History

J. Safra Sarasin Holding’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.98M Buy
107,839
+34,781
+48% +$560K 0.03% 266
2026
Q1 		$1.43M Sell
73,058
-15,213
-17% -$452K 0.02% 243
2025
Q4 		$2.75M Buy
88,271
+36,568
+71% +$1M 0.04% 173
2025
Q3 		$1.12M Sell
51,703
-119,416
-70% -$2.15M 0.02% 302
2025
Q2 		$2.39M Buy
171,119
+98,447
+135% +$1.34M 0.04% 191
2025
Q1 		$980K Buy
72,672
+36,219
+99% +$617K 0.02% 330
2024
Q4 		$699K Buy
+36,453
New +$793K 0.01% 377

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

J. Safra Sarasin Holding's VRDN Position: Q2 2026 in Review

J. Safra Sarasin Holding increased its Viridian Therapeutics (VRDN) stake by 48% in Q2 2026, buying an estimated $560K and bringing the position to 107,839 shares worth $1.98M. The position accounts for 0.03% of the portfolio, ranked #266.

J. Safra Sarasin Holding first reported a position in VRDN in Q4 2024 and has held it in 7 quarters since. The position peaked at $2.75M in Q4 2025. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • J. Safra Sarasin Holding held 107,839 shares of Viridian Therapeutics worth $1.98M as of Q2 2026.
  • J. Safra Sarasin Holding bought 34,781 Viridian Therapeutics shares in Q2 2026, an estimated $560K.
  • Viridian Therapeutics made up 0.03% of J. Safra Sarasin Holding's portfolio in Q2 2026, its #266 holding.
  • J. Safra Sarasin Holding first reported a position in Viridian Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • J. Safra Sarasin Holding's Viridian Therapeutics position peaked at $2.75M in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on J. Safra Sarasin Holding's 13F filing for Q2 2026, filed 31 Jul 2026.